Autonomous labs guided by AI can operate with increasing independence and are beginning to outperform human researchers.

Angelini Pharma has signed a definitive agreement to acquire Catalyst Pharmaceuticals for a total equity value of nearly $4.1bn.

Novo Nordisk has had a difficult year, faced with intense competition in the obesity space; however, the company’s Wegovy pill is offering a route to greener financial pastures.

This deal aligns with GSK's focus on addressing the complications of obesity, while restocking its pipeline amid key patent expiries.

Ginkgo Bioworks CEO Jason Kelly discusses the company’s work on autonomous labs and their impact on biopharma R&D.

Halozyme Hypercon has signed an exclusive global collaboration and licence agreement with Oruka Therapeutics to develop ORKA-001 using Hypercon Technology.

Daiichi Sankyo has entered into a collaboration with Paris-based Waiv intended at digital pathology biomarker discovery for an ADC programme.

When Eli Lilly's Lebanon campus is complete, it will manufacture several of the pharma's APIs and genetic medicines to serve US patients.

Novo Nordisk is set to launch Ozempic, its oral GLP-1 receptor agonist pill for adults with type 2 diabetes, in the US.

MSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML).

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Sunshine Lake Pharma, Lannett and its wholly owned subsidiary Lanexa Biologics have received FDA approval for Langlara.